文献速递间质性肺疾病

INPULSIS 试验中特发性肺纤维化急性加重的分析

Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis.
PubMed 文献 · Eur Respir J · 2017-05-19

基于 INPULSIS 试验数据,分析 IPF 急性加重的危险因素及尼达尼布对加重风险与结局的影响。急性加重风险与基线 FVC 较低、使用 supplemental oxygen、使用抗酸药、安慰剂治疗及吸烟相关;尼达尼布对加重后死亡率无显著影响。研究者报告的急性加重与裁定确认/疑似的急性加重在危险因素和结局上相似。

要点

  • 基线 FVC 越低、使用 supplemental oxygen 或抗酸药、安慰剂治疗及吸烟与急性加重风险升高相关。
  • 尼达尼布对急性加重后死亡率无显著影响。
  • 研究者报告的急性加重与裁定确认/疑似的急性加重在危险因素和结局上相似。

核心结论

  • 研究者报告的 IPF 急性加重与裁定确认/疑似的急性加重具有相似的危险因素和结局。
  • 尼达尼布对急性加重后死亡率无显著影响。

研究设计与样本

  • 基于 INPULSIS 试验数据的分析,研究对象为特发性肺纤维化患者。

主要发现

  • 急性加重风险与基线 FVC 较低、基线使用 supplemental oxygen、基线使用抗酸药、安慰剂治疗及吸烟相关。
  • 研究者报告的急性加重与裁定确认/疑似急性加重后的死亡率相似。
  • 尼达尼布对急性加重后死亡风险无显著影响。

临床怎么用

  • 关注基线 FVC 较低、使用 supplemental oxygen 或抗酸药、吸烟的 IPF 患者,其急性加重风险较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Time to first investigator-reported acute exacerbation was a key secondary end-point in the INPULSIS trials of nintedanib in patients with idiopathic pulmonary fibrosis (IPF).We used the INPULSIS trial data to investigate risk factors for acute exacerbation of IPF and to explore the impact of nintedanib on risk and outcome of investigator-reported and adjudicated confirmed/suspected acute exacerbations. Mortality following these events and events adjudicated as not acute exacerbations was analysed using the log rank test.Risk of acute exacerbations was most strongly associated with the following variables: baseline forced vital capacity (higher risk with lower value), baseline supplemental oxygen (higher risk with use), baseline antacid medication (higher risk with use), treatment (higher risk with placebo), and for confirmed/suspected acute exacerbations, cigarette smoking. Mortality was similar following investigator-reported and adjudicated confirmed/suspected acute exacerbations. Nintedanib had no significant effect on risk of mortality post-exacerbation.Investigator-reported acute exacerbations of IPF are associated with similar risk factors and outcomes as adjudicated confirmed/suspected acute exacerbations.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Collard HR, Richeldi L, Kim DS, et al. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Eur Respir J. 2017. PMID: 28526798. doi:10.1183/13993003.01339-2016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。